Jupiter Neurosciences Inc., a clinical-stage pharmaceutical company developing JOTROL, a patented resveratrol-based platform, ...

Jupiter Neurosciences (JUNS) announced it has entered into an agreement with Catalent Pharma Solutions for the production of JOTROL softgel ...

Jupiter, Florida, Feb. 03, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: JUNS) (“Jupiter” or the “Company”), a clinical-stage pharmaceutical company developing JOTROL™, a patented resveratrol-based platform, ...

JUPITER, FL - Jupiter Neurosciences, Inc. (NASDAQ: JUNS), a clinical-stage pharmaceutical company currently valued at $34.1 million, has announced a partnership with Catalent (NYSE:CTLT) Pharma ...